Novo long-acting GLP-1 antidiabetic drug success – health Sohu

Liu Yanjun, director of the PLA No.306 Hospital, the army diabetes center, transferred from tomato biopharmaceutical observation

(Novo Nordisk) giant Novo Nordisk Diabetes in the research of a new long-acting glucagon like peptide -1 (GLP-1) receptor agonist semaglutide (cable Maroo peptide) in fifth phase III clinical trials (SUSTAIN 5) successfully, the result showed that the semaglutide control and the effect of lowering blood sugar significantly poor slimming effect the group of type 2 diabetes in the blood glucose level of basal insulin therapy.

SUSTAIN 5 study was carried out in 397 cases of patients with type 2 diabetes mellitus, the investigation of the 0.5mg and 1.0mg dose semaglutide (subcutaneous injection, once a week) compared with the placebo, safety and efficacy as an adjunctive therapy combined with insulin or insulin based + metformin treatment for 30 weeks.

data show that, compared with the placebo group, 0.5mg dose and 1.0mg dose of semaglutide (subcutaneous injection, once a week) significantly improve the realization of the 2 treatment group blood glucose level significantly, baseline A1c (HbA1c, average 8.4%) decreased by 1.4% and 1.8% respectively, the placebo group HbA1c decreased 0.1%. At the end of the study, 0.5mg dose and 1.0mg dose of semaglutide (subcutaneous injection, once a week) in the 2 treatment groups were reduced by 10% and the insulin dose in the placebo group was only reduced by 3%.

In addition

, 0.5mg dose and 1.0mg dose of semaglutide (subcutaneous injection, once a week) 2 treatment groups were 61% and 79% of the patients reached HbA1c < 7% (American ADA standard and the European EASD standards) treatment targets, the placebo group was only 11%.

weight, 0.5mg dose and 1.0mg dose of semaglutide (subcutaneous injection, 2 times per week) in patients treated with weight from baseline (average weight 92 kg) reduced 3.7 kg and 6.4 kg respectively, the placebo group reduced body weight 1.4 kg.

security, semaglutide showed good safety and tolerability. The most common adverse events were nausea, 0.5mg dose and 1.0mg dose of semaglutide (subcutaneous injection, once a week) in the 2 treatment groups were 11% and 17% in the placebo group, respectively, and the rate was higher in the placebo group than in the placebo group (). The incidence of symptomatic hypoglycemia was 8% and significantly higher in the placebo group than in the placebo group, with a rate of 5% in the placebo group, respectively. The rate was 11%. 0.5mg dose and 1.0mg dose semagl>